JHVEPhoto/iStock Editorial via Getty Images
Teva Pharmaceutical (NYSE:TEVA) and South Korean generic drugmaker Samsung Bioepis announced Monday the U.S. commercial availability of Epysqli, a biosimilar drug targeting AstraZeneca’s (NASDAQ:AZN) rare disease therapy Soliris (eculizumab).
The duo said that Epysqli will be launched at a 30% discount